

De waarde van de CRP-sneltest bij exacerbaties van COPD

Rogier Hopstaken^a, Sandra Schipper^b

^a huisarts Gezondheidscentrum Meerhoven, Eindhoven, tevens Saltro diagnostisch centrum, Utrecht

^b student geneeskunde, Universiteit van Maastricht

Referenties

1. Hopstaken RM, Muris JWM, Knottnerus JA, Kester ADM, Rinkens PELM, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. *Br J Gen Pract* 2003;53:358-64.
2. Cals, JWL, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C-reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. *Brit Med J* 2009;338:b1374.
3. Verheij ThJM, Hopstaken RM, Prins JM, Salomé PhL, Bindels PJ, Ponsioen BP†, Sachs APE, Thiadens HA, Verlee E. M78 NHG-Standaard Acut hoesten (eerste herziening). *Huisarts Wet* 2011; 54(2):68-92.
4. Hopstaken R, Verdijk N, Van den Broek N, Verspaandonk K, Meulepas M, Helder C, Keyzer J. CRP-sneltest in de dagelijkse praktijk. *Huisarts Wet* 2012;55(9):388-92.
5. Smeele IJM, van Weel C, van Schayck CP, van der Molen T, Schermer T, Sachs APE, Muris JWM, Chavannes NH, Kolnaar BGM, Grol MH, Geijer RMM. NHG-Standaard COPD. *Huisarts Wet* 2007;50(8):362-79.
6. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006; CD004403.
7. Puhan MA, Vollenweider D. Respir. Res. 2007 Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C: Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. *Respiratory research* 2007, 8:30.
8. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007; 176(6): 532–555.
9. Weis N, Almdal T. C-reactive protein—can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? *Eur J Intern Med.* 2006; 17(2):88-91.
10. Hopstaken RM, Stobberingh EE, Knottnerus JA, et al. Clinical items not helpful in differentiating viral from bacterial lower respiratory tract infections in general practice. *J Clin Epidemiol* 2005; 58:175-83.

11. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. *Current Opinion in Pulmonary Medicine* 2009, 15:120–125.
12. de Torres JP, Cordoba-Lanus E, Lo´pez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. *Eur Respir J* 2006;27: 902–907.
13. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007 Feb 1;175(3):250e5.
14. Man P, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. *Thorax* 2006;61:849–853.
15. Shabaan R, Kony S, Driss F. *et al* Change in C-reactive protein levels and FEV₁ decline: a longitudinal population-based study. *Respir Med* 2006. 1002112–2120.2120.
16. Perera WR , Hurst JR , Wilkinson TM , et al . Inflammatory changes, recovery and recurrence at COPD exacerbation. *Eur Respir J* 2007;29(3): 527-534 .